#clinicaltrials Tag

10 Jul

Posted at 10:33h in Clinical Trials

Most people think finding a research study is mainly a matching problem. They search by condition, age, location, and payment, then look for a study that seems to fit. Those details matter, but they are not the whole problem. For many patients, the harder issue is timing. A study can look perfect and still be unavailable because it has not opened yet, has already filled, or has moved into follow-up without accepting new participants.

That is why Hipa.ai treats study search as a regularly updated discovery problem, not a static list. The platform helps people browse clinical trials across the United States, with recruiting status visible on each listing and source data drawn from ClinicalTrials.gov and AACT, then rebuilt into its own index on a weekly cadence. Hipa.ai does not ask patients to guess whether an old page is still useful. It keeps the practical question in front of them — is this study open now, and what should I do next?

17 Jun

Posted at 21:03h in Laboratories, Medical Imaging
[caption id="attachment_74343" align="aligncenter" width="500"]radiopharmaceuticals-pexels.jpg Pexels[/caption]

Preclinical Studies with Radiopharmaceuticals: IND-Enabling Guidance and Study Design

 

Introduction

Preclinical evaluation is an integral part of the development of investigational new drugs (IND), including radiopharmaceuticals. Radiopharmaceuticals are radio-labelled formulations used for diagnostic, therapeutic, and disease monitoring purposes within the context of both nuclear medicine and pharmaceutical research. While diagnostic radiopharmaceuticals are used to image organ function, trace biological processes, and quantify metabolism or IND target engagement, therapeutic radiopharmaceuticals are typically used in the field of oncology, whereby ionising radiation of a conjugated radionuclide induces targeted cell death. Because radiopharmaceuticals require the use of radioactive compounds, regulatory bodies such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) require stringent controls around their development, manufacturing, handling, transport, and use. This article will consider guidance specifically surrounding the development of preclinical radiopharmaceutical research studies, considering imaging requirements, dosimetry, and toxicology, and highlighting how sponsors can enable IND success through partnership with a preclinical imaging provider experienced in nuclear medicine.

04 Jun

Posted at 11:30h in Global Health
[caption id="attachment_74080" align="aligncenter" width="500"]clinical-research-europe-pexels Photo by Pavel Danilyuk[/caption] Clinical research in Europe is conducted within one of the most structured and closely regulated environments in the world. While European countries share many common regulatory principles, the practical implementation of clinical trials often differs from one jurisdiction to another. Ethics review procedures, administrative timelines, language requirements, healthcare systems, and site capabilities can vary significantly across the region. Because of this complexity, sponsors frequently rely on a clinical research organisation Europe model to coordinate activities and maintain consistency throughout the study lifecycle. A clinical research organisation operating in Europe serves as a bridge between sponsors, investigators, regulatory authorities, and clinical sites. Its role is not limited to a single stage of research. Instead, it supports multiple operational functions that help transform a study concept into a structured and compliant clinical trial.

Supporting Study Planning and Feasibility

Before a trial begins, sponsors must determine whether the study can be conducted efficiently in the selected countries and sites. This process involves evaluating patient availability, investigator experience, regulatory timelines, and operational requirements. A clinical research organisation Europe may assist with: ● feasibility assessments, ● site identification and qualification, ● country selection strategies, ● recruitment potential analysis, ● evaluation of operational risks and timelines. Early planning helps reduce uncertainty and supports realistic expectations regarding study execution.

26 Mar

Posted at 12:47h in Personalized Medicine, Pharmacology
[caption id="attachment_72942" align="aligncenter" width="500"]Integrating Pharmacokinetics Services Photo by Robert Katzki on Unsplash[/caption] Pharmacokinetics services are rapidly evolving as artificial intelligence (AI) and advanced modeling tools reshape the landscape of modern drug discovery. By combining traditional pharmacokinetic analysis with data-driven technologies, researchers can better predict how drugs behave in the human body, optimize dosing strategies, and accelerate development timelines. This integration represents a major shift toward more efficient, precise, and cost-effective pharmaceutical innovation.

Introduction to the Convergence of PK and AI

Drug discovery has traditionally relied on a combination of laboratory experiments, animal studies, and clinical trials to understand drug behavior. While effective, this approach is time-consuming, expensive, and often limited by uncertainty. Today, the integration of pharmacokinetics services with AI and modeling tools is transforming this process. AI algorithms can analyze vast datasets, identify patterns, and generate predictions that would be impossible through manual analysis alone. When combined with pharmacokinetic expertise, these tools provide deeper insights into drug absorption, distribution, metabolism, and excretion (ADME).

11 Jul

Posted at 12:51h in AI and HealthCare, Medical Equipment
[caption id="attachment_69484" align="aligncenter" width="500"]remote-monitoring-medical-research Photo by MedPoint 24[/caption] Remote monitoring is rapidly becoming a central component of modern clinical research. Driven by advancements in digital health technologies, wearable sensors, and telecommunication platforms, remote monitoring allows investigators to collect real-time patient data without requiring participants to travel to study sites. This shift toward decentralized clinical trials and virtual monitoring has significant implications for the future of research—making studies more accessible, cost-effective, and representative. At its core, remote monitoring involves the collection of health-related data from participants outside of traditional clinical settings, using connected devices such as smartwatches, mobile apps, biosensors, and electronic health records (EHRs). Data collected may include vital signs, medication adherence, physical activity, symptom reporting, or even biometric data such as ECGs or glucose levels. The COVID-19 pandemic accelerated the adoption of remote monitoring, revealing both its vast potential and practical limitations. In 2025 and beyond, the challenge lies in striking a balance—leveraging the benefits while addressing regulatory, technical, and ethical complexities.

11 Jul

Posted at 10:00h in Clinical Trials, Electronic Records
[caption id="attachment_69467" align="aligncenter" width="500"]importance-data-management-clinical-trials Photo by Christina Morillo[/caption] Every clinical trial produces mountains of data. From patient enrollment logs and lab results to adverse event reports and protocol deviations, clinical data is the backbone of every decision made during drug or device development. Yet, collecting data is only the beginning — it’s how that data is managed, validated, and interpreted that determines a study’s success. In the age of decentralized trials, real-time analytics, and global regulatory oversight, the importance of reliable clinical data management can’t be overstated. High-quality data doesn’t just support regulatory submissions — it protects patient safety, ensures compliance, and strengthens confidence in results.

Why Is Clinical Data Management No Longer Just a Technical Task?

Gone are the days when data management was treated as an afterthought or a purely technical role. Today, it’s central to trial strategy. From the very beginning of a study, data management professionals are involved in shaping case report forms (CRFs), planning how endpoints will be measured, and ensuring systems are in place to capture data accurately and securely. This shift in thinking is due to the increasing complexity of trial protocols, the rise in remote data capture tools, and the growing pressure from regulators for traceable, auditable datasets. Sponsors and CROs alike are realizing that data management is no longer an isolated function — it’s the foundation of trial integrity.

What Does a Modern Clinical Trial Data Management Service Include?

A robust clinical trial data management service goes far beyond database design. It encompasses an ecosystem of systems, people, and processes designed to ensure that every data point collected is clean, consistent, and ready for analysis. Typical services include:
  • CRF design tailored to protocol endpoints
  • Electronic Data Capture (EDC) system configuration
  • Real-time data monitoring and discrepancy resolution
  • Medical coding using standard dictionaries (e.g., MedDRA, WHO Drug)
  • Query management and investigator communication
  • Data cleaning, validation, and database lock support
The goal is simple: to transform complex, multi-source data into a reliable and statistically sound dataset that regulators can trust — and that sponsors can use to make decisions.

11 Mar

Posted at 17:32h in Trials
clinical-trials-faster-research-outcomes Clinical trials are essential for advancing medical science and developing new treatments. However, the process can often be slow and cumbersome, delaying the delivery of innovative therapies to patients in need. Emerging technologies are transforming this landscape, providing tools that make clinical trials more efficient and effective. As you explore the world of clinical trials, understanding the importance of efficient tools becomes paramount. These tools significantly accelerate clinical trial timelines, ensuring quicker access to vital medical interventions. The healthcare industry is witnessing a rapid evolution in how research is conducted, with technology playing a pivotal role in this transformation. Platforms like Patiro are instrumental in this shift, offering innovative ways to connect qualified patients with clinical trials.

The Impact of Technology on Clinical Trials

Technology is reshaping the way clinical trials are conducted, primarily by reducing enrollment delays. This crucial phase often poses significant challenges due to stringent criteria and the necessity for a diverse pool of participants. With advanced platforms leveraging data analytics and AI-driven solutions, researchers can swiftly identify and recruit suitable candidates. This expedites the process and enhances the quality of research outcomes by ensuring a representative sample. The integration of digital tools has further enabled remote monitoring and virtual trials, reducing geographical barriers that traditionally hindered participant enrollment. This shift broadens access and allows continuous data collection in real-time, increasing accuracy and reliability. The time saved in these processes directly contributes to faster trial completion and quicker dissemination of results. In addition to enrollment efficiencies, technological innovations facilitate better data management throughout the trial phases. Automation in data entry and processing minimizes human error, maintaining high standards of accuracy and compliance. Consequently, this fosters a more streamlined workflow, significantly cutting down on administrative burdens faced by research teams. Machine learning algorithms have revolutionized patient matching and protocol optimization, reducing the time spent on manual screening processes by up to 60%. These intelligent systems can analyze vast amounts of electronic health records, identifying potential participants who meet specific trial criteria within minutes rather than weeks. Additionally, predictive analytics help researchers anticipate and address potential bottlenecks before they impact trial timelines, ensuring smoother execution throughout the study lifecycle.

29 Jun

Posted at 00:00h in Author Interviews
MedicalResearch.com Interview with: [caption id="attachment_57716" align="alignleft" width="200"]Scott Gray Scott Gray[/caption] Scott Gray: Founder and CEO of Clincierge, the global leader in patient support services for clinical trials. With a team of patient coordinators around the world, Clincierge helps patients and their caregivers navigate the logistics of clinical trial participation, including prepaid air travel, ground transportation, and lodging as well as rapid reimbursements, translation and interpretation services, and individual solutions for trial participants in remote locations or with complex medical needs. For more information, visit clincierge.com. MedicalResearch.com: What is the mission of Clincierge? ClinciergeResponse: Our mission is to improve the performance of clinical trials around the world by better managing the patient experience through highly personalized patient support services and efficient processes carried out by a team of experienced travel and logistics professionals.